Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian follow-upMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency